Q32 Bio (NASDAQ: QTTB) adds $75M ATM common stock capacity
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Q32 Bio Inc. entered a new phase of its at-the-market stock offering program by filing an additional prospectus supplement that covers up to $75,000,000 of common stock to be sold through Cantor Fitzgerald & Co. under an existing Controlled Equity Sales Agreement.
The company previously sold $14,200,000 of common stock under an earlier prospectus supplement, which is now fully used and terminated. Future sales of the additional shares, if any, will be made under Q32 Bio’s effective Form S-3 shelf registration statement.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Prior ATM sales: $14,200,000
New ATM capacity: $75,000,000
Shelf registration file number: 333-286491
+1 more
4 metrics
Prior ATM sales
$14,200,000
Aggregate common stock sold under prior prospectus supplement
New ATM capacity
$75,000,000
Aggregate offering price of additional common stock under new prospectus supplement
Shelf registration file number
333-286491
Form S-3 shelf registration used for additional shares
Form S-3 effective date
April 21, 2025
Date SEC declared Q32 Bio’s Form S-3 effective
Key Terms
Controlled Equity Sales Agreement, at-the-market offering program, prospectus supplement, shelf registration statement on Form S-3, +1 more
5 terms
Controlled Equity Sales Agreement financial
"entered into a Controlled Equity Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co."
at-the-market offering program financial
"with respect to an at-the-market offering program pursuant to which the Company may offer and sell"
An at-the-market offering program lets a company sell newly issued shares directly into the open market at current trading prices through a broker, rather than issuing a large block of stock all at once. It matters to investors because it provides the company a flexible way to raise cash over time, which can dilute existing shares gradually and affect earnings per share and stock price depending on how much and when shares are sold—think of it as a faucet the company can open or close to add supply to the market.
prospectus supplement regulatory
"The Company previously filed a prospectus supplement with the Securities and Exchange Commission"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
shelf registration statement on Form S-3 regulatory
"pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-286491)"
A shelf registration statement on Form S-3 is a pre-approved filing with the Securities and Exchange Commission that lets an eligible public company register securities in advance and sell them later in one or more offerings without repeating the full registration process. Think of it like a pre-approved funding line: it gives management the flexibility to raise capital quickly when market conditions are right, a move that can affect share supply, dilution and investor returns, so investors monitor it as a signal of potential financing activity.
aggregate offering price financial
"relating to the offer and sale of shares of Common Stock having an aggregate offering price of up to $14,200,000"
The aggregate offering price is the total dollar amount that will be raised if all the securities in an offering are sold at the stated offering price, before fees or expenses are taken out. Investors use it to gauge the size of the fundraising and its potential effects—such as how much cash the company will get and how much existing ownership might be reduced—similar to totaling every item’s price in a shopping cart to see the full bill.
FAQ
What did Q32 Bio (QTTB) announce regarding its at-the-market program?
Q32 Bio expanded its at-the-market stock offering capacity by filing an additional prospectus supplement for up to $75,000,000 of common stock. These potential sales will occur through Cantor Fitzgerald & Co. under an existing Controlled Equity Sales Agreement and the company’s Form S-3 shelf.
How much has Q32 Bio already sold under its prior ATM prospectus?
Q32 Bio has sold an aggregate of $14,200,000 of common stock under its prior prospectus supplement. With that amount fully sold, the prior prospectus supplement has been terminated, and no further shares will be offered or sold under that earlier document.
What is the size of Q32 Bio’s new additional ATM capacity?
The new additional capacity under Q32 Bio’s at-the-market program covers common stock with an aggregate offering price of up to $75,000,000. Any such sales would be made through Cantor Fitzgerald & Co. pursuant to the company’s effective Form S-3 shelf registration statement.
Who is acting as sales agent for Q32 Bio’s at-the-market offering?
Cantor Fitzgerald & Co. is acting as the Sales Agent for Q32 Bio’s at-the-market offering program. The company may offer and sell its common stock, from time to time at its sole discretion, through Cantor Fitzgerald & Co. under the Controlled Equity Sales Agreement.